Abbvie Inc ABBV

$286.20 +2.66 (0.94%)

Valuation

Market cap
505,555,840,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
P/E (trailing)
22.82
P/E (forward)
20.94
Profit margin
6.91%
Debt to equity
-17.83

Trading

Volume
8,673,601
Avg volume
4,967,148
Day's range
$284.85 – $290.23
Shares out
1,767,616,000
Stochastic %K
17%
Beta
0.20
Analysts
Moderate Buy
Price target
$314.50

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

55X_ROI_Q1_2026 Nov 20, 8:03 PM
$SLS $3B Market Cap for a revolutionary WT1+ Cancer Vaccine that will Generate $10B a year just in the AML Remission Setting. • manipulation offering the Investment Opportunity of our Lifetimes. GPs + Keytruda $MRK Phase 2 MOS of 18.4 Months in Advanced Ovarian Cancer/ is better than Standard of Care Elahere 16.46 months. $ABBV bought $IMGN Elahere for $10.1B Get em while they'e cheap.
0 replies
55X_ROI_Q1_2026 Nov 20, 7:49 PM
$SLS $MRK $ABBV Ceo transcript estimating Cr2 market Scope. Revenue could top $10B Per YEAR --- Just for AML Remission Maintenance Will set record patient uptake rates - 75% is current standard w new drugs - 2x 3x OS Advantage / Pristine Safety 100% QoL /in home Sub Q • 12,500 CR2/3 Patients • $500K Per Patient • $6.25B TAM Just for the Initial P3 Setting 75% uptake -- $4.7B in Actual Revenue Just from the Cr2/3 setting that $4B alone is worth 6x -8x multiple •• $24B - $28B 215M shares Float / $24B $111 Per SLS SHARE * - includes Latest Offering - again just Cr2/3 - which is inaccurate, as GPS P3 MOS for Cr2/ and LATER - is as good as Standard of Care / Onureg in CR1 GPS will Also be Valued for this Much Larger Indication 50,000 AML CR1 Patients Each YEAR --- the math is boggling. the current discounted share price is an aberration. $MRNA $XBI
0 replies
shoc24 Nov 20, 5:42 PM
Been a crazy few weeks in the market but there is still opportunity if you're investing long term. $ABBV is ranked #25 in healthcare quality with a score of 82. I used Stock Meadow's scoring model. Build your own model and backtest it if you don't agree with mine.
0 replies
Gebinator Nov 20, 4:10 PM
$SLS there are likely many factors involved in GPS patient response rate -- chief among them the level of WT1 expression in their biology, their state of health --particularly whether previous aggressive chemo and/or difficult SC transplant has compromised their body, mind and spirit. Age a factor too, among others. To improve response rate, I believe there's the possibility of pre-screening oncology patients for WT1 expression and levels in their system. Most critically, though, perhaps is to potentially start GPS immunotherapy EARLIER in a patient's journey -- ie. such as CR1 and even in adjuvant settings. And, as we've speculated, continuing GPS maintenance therapy ad infinitum -- until potential relapse or death. Of course, the composition of GPS may also be upgraded to next-generation heptavalent GPS+, to provide a 7-peptide string will potentially improve response rate in the future. All some things for $JNJ, $MRK, $ABBV, $LLY and others to consider in the near future 😉
0 replies
Techdamentals Nov 20, 3:59 PM
One number from $ABBV's latest report: revenue was $17.40 billion in the quarter ended September 30, 2026, up 10.3% from $15.78 billion a year earlier. Skyrizi sales grew 22.7%. The card lays out revenue, margins, cash and debt from the company's own reported numbers, so see the fundamentals and sign up for free. Educational, not advice. See the fundamentals below 👇 https://techdamentals.com/v3/ABBV?ref=st
0 replies
openclassaction2 Nov 20, 3:14 PM
$ABBV a suit alleges abbvie failed to warn juvederm fillers can cause delayed granulomas, per open class actions. lawsuit stage, nothing to claim. warnings are the product too
0 replies
HydrogenH2 Nov 20, 3:13 PM
$ABBV $JNJ Let me guess ?? Another "PUMP & TRUMP " day ??
0 replies
SellasGPS24BAT14 Nov 20, 2:44 PM
$ABBV $BMY $JNJ $PFE $SLS 0 FDA approved non toxic Cancer treatments. GPS will be the first off the shelf 0 Toxicity cancer drug ever. ✌️🙏❤️‍🩹
0 replies